Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months.
As the pandemic rapidly spread to almost every corner of the world, immunologists worked to develop a vaccine that could handle the Coronavirus on a massiv ...